{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T21:24:39Z","timestamp":1794345879616,"version":"4.9.0"},"reference-count":148,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T00:00:00Z","timestamp":1665100800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: CardioOncology"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.jaccao.2022.08.009","type":"journal-article","created":{"date-parts":[[2022,11,15]],"date-time":"2022-11-15T23:59:57Z","timestamp":1668556797000},"page":"427-441","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":119,"title":["AL Amyloidosis for Cardiologists"],"prefix":"10.1016","volume":"4","author":[{"given":"Ashutosh D.","family":"Wechalekar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5074-2078","authenticated-orcid":false,"given":"Marianna","family":"Fontana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Cristina","family":"Quarta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela","family":"Liedtke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaccao.2022.08.009_bib1","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1186\/s13023-020-01525-2","article-title":"The amyloidosis forum: a public private partnership to advance drug development in AL amyloidosis","volume":"15","author":"Blank","year":"2020","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jaccao.2022.08.009_bib2","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/1750-1172-7-54","article-title":"AL amyloidosis","volume":"7","author":"Desport","year":"2012","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jaccao.2022.08.009_bib3","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1182\/bloodadvances.2018016402","article-title":"Epidemiology of AL amyloidosis: a real-world study using US claims data","volume":"2","author":"Quock","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.jaccao.2022.08.009_bib4","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1159\/000495455","article-title":"Recent advances in the diagnosis, risk stratification, and management of systemic light-chain amyloidosis","volume":"141","author":"Vaxman","year":"2019","journal-title":"Acta Haematol"},{"key":"10.1016\/j.jaccao.2022.08.009_bib5","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1200\/JCO.2011.38.5724","article-title":"Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements","volume":"30","author":"Kumar","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jaccao.2022.08.009_bib6","doi-asserted-by":"crossref","first-page":"12","DOI":"10.4065\/mcp.2010.0480","article-title":"Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score","volume":"86","author":"Kumar","year":"2011","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jaccao.2022.08.009_bib7","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1182\/blood.2019000834","article-title":"A\u00a0prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib","volume":"134","author":"Manwani","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jaccao.2022.08.009_bib8","first-page":"958","article-title":"A\u00a0changing landscape of mortality for systemic light chain amyloidosis","volume":"7","author":"Barrett","year":"2019","journal-title":"J\u00a0Am Coll Cardiol HF"},{"key":"10.1016\/j.jaccao.2022.08.009_bib9","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1182\/blood-2016-11-751628","article-title":"Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death","volume":"129","author":"Muchtar","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jaccao.2022.08.009_bib10","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/ejh.13472","article-title":"Patient outcomes in light chain (AL) amyloidosis: the clock is ticking from symptoms to diagnosis","volume":"105","author":"Schulman","year":"2020","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jaccao.2022.08.009_bib11","doi-asserted-by":"crossref","first-page":"3604","DOI":"10.1038\/s41375-021-01297-z","article-title":"Outcomes among newly diagnosed AL amyloidosis patients with a very high NT-proBNP: implications for trial design","volume":"35","author":"Vaxman","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.jaccao.2022.08.009_bib12","doi-asserted-by":"crossref","first-page":"3","DOI":"10.14797\/mdcj-8-3-3","article-title":"The amyloidoses: clinical features, diagnosis and treatment","volume":"8","author":"Baker","year":"2012","journal-title":"Methodist Debakey Cardiovasc J"},{"key":"10.1016\/j.jaccao.2022.08.009_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/asheducation-2017.1.1","article-title":"AL amyloidosis: from molecular mechanisms to targeted therapies","volume":"2017","author":"Merlini","year":"2017","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.jaccao.2022.08.009_bib14","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-15424-3","article-title":"Proteotoxicity in cardiac amyloidosis: amyloidogenic light chains affect the levels of intracellular proteins in human heart cells","volume":"7","author":"Imperlini","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.jaccao.2022.08.009_bib15","doi-asserted-by":"crossref","first-page":"4614","DOI":"10.1096\/fj.15-272179","article-title":"Novel mitochondrial protein interactors of immunoglobulin light chains causing heart amyloidosis","volume":"29","author":"Lavatelli","year":"2015","journal-title":"FASEB J"},{"key":"10.1016\/j.jaccao.2022.08.009_bib16","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1001\/jama.2020.5493","article-title":"Systemic amyloidosis recognition, prognosis, and therapy: a systematic review","volume":"324","author":"Gertz","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.jaccao.2022.08.009_bib17","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1038\/nrneph.2013.171","article-title":"Pathophysiology and treatment of systemic amyloidosis","volume":"9","author":"Gillmore","year":"2013","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.jaccao.2022.08.009_bib18","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1056\/NEJMra023144","article-title":"Molecular mechanisms of amyloidosis","volume":"349","author":"Merlini","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaccao.2022.08.009_bib19","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/s00392-019-01490-2","article-title":"When and how do patients with cardiac amyloidosis die?","volume":"109","author":"Escher","year":"2020","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.jaccao.2022.08.009_bib20","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1080\/13506129.2016.1208081","article-title":"Depression and anxiety in patients with AL amyloidosis as assessed by the SF-36 questionnaire: experience in 1226 patients","volume":"23","author":"Shu","year":"2016","journal-title":"Amyloid"},{"key":"10.1016\/j.jaccao.2022.08.009_bib21","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13023-016-0564-2","article-title":"The burden of amyloid light chain amyloidosis on health-related quality of life","volume":"12","author":"Bayliss","year":"2017","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jaccao.2022.08.009_bib22","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1161\/CIRCULATIONAHA.104.489187","article-title":"Diagnosis and management of the cardiac amyloidoses","volume":"112","author":"Falk","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.jaccao.2022.08.009_bib23","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.jcmg.2019.10.011","article-title":"Multiparametric echocardiography scores for the diagnosis of cardiac amyloidosis","volume":"13","author":"Boldrini","year":"2020","journal-title":"J\u00a0Am Coll Cardiol Img"},{"key":"10.1016\/j.jaccao.2022.08.009_bib24","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1080\/03007995.2017.1297930","article-title":"Disease burden of systemic light-chain amyloidosis: a systematic literature review","volume":"33","author":"Lin","year":"2017","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jaccao.2022.08.009_bib25","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s40271-017-0273-5","article-title":"Light chain (AL) amyloidosis: the journey to diagnosis","volume":"11","author":"McCausland","year":"2018","journal-title":"Patient"},{"key":"10.1016\/j.jaccao.2022.08.009_bib26","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1007\/s12325-015-0250-0","article-title":"Light chain amyloidosis: patient experience survey from the amyloidosis research consortium","volume":"32","author":"Lousada","year":"2015","journal-title":"Adv Ther"},{"key":"10.1016\/j.jaccao.2022.08.009_bib27","doi-asserted-by":"crossref","first-page":"e454","DOI":"10.1097\/HS9.0000000000000454","article-title":"Systemic AL amyloidosis: current approaches to diagnosis and management","volume":"4","author":"Fotiou","year":"2020","journal-title":"HemaSphere"},{"key":"10.1016\/j.jaccao.2022.08.009_bib28","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1159\/000443200","article-title":"Immunoglobulin light-chain amyloidosis: from basics to new developments in diagnosis, prognosis and therapy","volume":"135","author":"Muchtar","year":"2016","journal-title":"Acta Haematologica"},{"key":"10.1016\/j.jaccao.2022.08.009_bib29","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1136\/heartjnl-2016-310704","article-title":"Light-chain cardiac amyloidosis: strategies to promote early diagnosis and cardiac response","volume":"103","author":"Grogan","year":"2017","journal-title":"Heart"},{"key":"10.1016\/j.jaccao.2022.08.009_bib30","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/ejh.13681","article-title":"Impact of time to diagnosis on Mayo stages, treatment outcome, and survival in patients with AL amyloidosis and cardiac involvement","volume":"107","author":"Oubari","year":"2021","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jaccao.2022.08.009_bib31","first-page":"117","article-title":"AL amyloidosis for the cardiologist and oncologist","volume":"1","author":"Witteles","year":"2019","journal-title":"J\u00a0Am Coll Cardiol CardioOnc"},{"key":"10.1016\/j.jaccao.2022.08.009_bib32","first-page":"467","article-title":"AL amyloidosis: current chemotherapy and immune therapy treatment strategies","volume":"3","author":"Bianchi","year":"2021","journal-title":"J\u00a0Am Coll Cardiol CardioOnc"},{"key":"10.1016\/j.jaccao.2022.08.009_bib33","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1080\/13506129.2018.1498782","article-title":"Seven factors predict a delayed diagnosis of cardiac amyloidosis","volume":"25","author":"Bishop","year":"2018","journal-title":"Amyloid"},{"key":"10.1016\/j.jaccao.2022.08.009_bib34","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1080\/14656566.2016.1274971","article-title":"New and developing therapies for AL amyloidosis","volume":"18","author":"Zumbo","year":"2017","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.jaccao.2022.08.009_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107612","article-title":"Diagnosis and management of systemic light chain AL amyloidosis","volume":"214","author":"Bhutani","year":"2020","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.jaccao.2022.08.009_bib36","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1002\/clc.23572","article-title":"Cardiac amyloidosis-a review of current literature for the practicing physician","volume":"44","author":"Ash","year":"2021","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.jaccao.2022.08.009_bib37","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1161\/CIRCRESAHA.121.318187","article-title":"Pathophysiology and therapeutic approaches to cardiac amyloidosis","volume":"128","author":"Griffin","year":"2021","journal-title":"Circ Res"},{"key":"10.1016\/j.jaccao.2022.08.009_bib38","doi-asserted-by":"crossref","first-page":"e60","DOI":"10.1016\/j.crvasa.2012.11.018","article-title":"Cardiac amyloidosis: a comprehensive review","volume":"55","author":"Fikrle","year":"2013","journal-title":"Cor Vasa"},{"key":"10.1016\/j.jaccao.2022.08.009_bib39","doi-asserted-by":"crossref","first-page":"5126","DOI":"10.1182\/blood-2010-06-290668","article-title":"Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features","volume":"116","author":"Kumar","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jaccao.2022.08.009_bib40","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/647238","article-title":"Clinical comparisons of two free light chain assays to immunofixation electrophoresis for detecting monoclonal gammopathy","volume":"2014","author":"Kim","year":"2014","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.jaccao.2022.08.009_bib41","first-page":"590","article-title":"How to screen for monoclonal gammopathy in patients with a suspected amyloidosis","volume":"3","author":"Rubinstein","year":"2021","journal-title":"J\u00a0Am Coll Cardiol CardioOnc"},{"key":"10.1016\/j.jaccao.2022.08.009_bib42","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.2215\/CJN.02740806","article-title":"Light-chain (AL) amyloidosis: diagnosis and treatment","volume":"1","author":"Sanchorawala","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.jaccao.2022.08.009_bib43","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1373\/clinchem.2008.117143","article-title":"Identification of amyloidogenic light chains requires the combination of serum-free light chain assay with immunofixation of serum and urine","volume":"55","author":"Palladini","year":"2009","journal-title":"Clin Chem"},{"key":"10.1016\/j.jaccao.2022.08.009_bib44","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1159\/000508022","article-title":"Confirming the diagnosis of amyloidosis","volume":"143","author":"Wisniowski","year":"2020","journal-title":"Acta Haematologica"},{"key":"10.1016\/j.jaccao.2022.08.009_bib45","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1002\/ajh.24433","article-title":"Immunoglobulin light chain amyloidosis: 2016 update on diagnosis, prognosis, and treatment","volume":"91","author":"Gertz","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jaccao.2022.08.009_bib46","doi-asserted-by":"crossref","first-page":"36","DOI":"10.15420\/aer.2013.2.1.36","article-title":"Mimics of hypertrophic cardiomyopathy\u2014diagnostic clues to aid early identification of phenocopies","volume":"2","author":"Sankaranarayanan","year":"2013","journal-title":"Arrhythm Electrophysiol Rev"},{"key":"10.1016\/j.jaccao.2022.08.009_bib47","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1080\/13506129.2018.1552852","article-title":"A\u00a0pilot study demonstrating cardiac uptake with 18F-florbetapir PET in AL amyloidosis patients with cardiac involvement","volume":"25","author":"Manwani","year":"2018","journal-title":"Amyloid"},{"key":"10.1016\/j.jaccao.2022.08.009_bib48","doi-asserted-by":"crossref","first-page":"e178","DOI":"10.1161\/CIRCULATIONAHA.111.069195","article-title":"Cardiac amyloidosis","volume":"126","author":"Quarta","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.jaccao.2022.08.009_bib49","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/j.jcmg.2018.07.005","article-title":"Research to practice","volume":"11","author":"Yang","year":"2018","journal-title":"J\u00a0Am Coll Cardiol Img"},{"key":"10.1016\/j.jaccao.2022.08.009_bib50","article-title":"The evolving role of cardiovascular magnetic resonance imaging in the evaluation of systemic amyloidosis","volume":"12","author":"Banypersad","year":"2019","journal-title":"Magn Reson Insights"},{"key":"10.1016\/j.jaccao.2022.08.009_bib51","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1161\/CIRCIMAGING.112.978627","article-title":"Quantification of myocardial extracellular volume fraction in systemic AL amyloidosis: an equilibrium contrast cardiovascular magnetic resonance study","volume":"6","author":"Banypersad","year":"2013","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.jaccao.2022.08.009_bib52","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1016\/j.jcmg.2009.08.008","article-title":"Delayed hyper-enhancement magnetic resonance imaging provides incremental diagnostic and prognostic utility in suspected cardiac amyloidosis","volume":"2","author":"Austin","year":"2009","journal-title":"J\u00a0Am Coll Cardiol Img"},{"key":"10.1016\/j.jaccao.2022.08.009_bib53","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1093\/ehjci\/jeu158","article-title":"The mosaic of the cardiac amyloidosis diagnosis: role of imaging in subtypes and stages of the disease","volume":"15","author":"Di Bella","year":"2014","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.jaccao.2022.08.009_bib54","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.amjcard.2008.09.105","article-title":"Diagnostic and prognostic utility of cardiovascular magnetic resonance imaging in light-chain cardiac amyloidosis","volume":"103","author":"Ruberg","year":"2009","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jaccao.2022.08.009_bib55","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jcmg.2009.09.023","article-title":"Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis","volume":"3","author":"Syed","year":"2010","journal-title":"J\u00a0Am Coll Cardiol Img"},{"key":"10.1016\/j.jaccao.2022.08.009_bib56","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.jacc.2007.10.049","article-title":"Cardiovascular magnetic resonance in clinically suspected cardiac amyloidosis: noninvasive imaging compared to endomyocardial biopsy","volume":"51","author":"Vogelsberg","year":"2008","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jaccao.2022.08.009_bib57","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1148\/radiol.2015141744","article-title":"Differential myocyte responses in patients with cardiac transthyretin amyloidosis and light-chain amyloidosis: a cardiac MR imaging study","volume":"277","author":"Fontana","year":"2015","journal-title":"Radiology"},{"key":"10.1016\/j.jaccao.2022.08.009_bib58","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s10741-014-9470-7","article-title":"Cardiovascular magnetic resonance for amyloidosis","volume":"20","author":"Fontana","year":"2015","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.jaccao.2022.08.009_bib59","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.jcct.2015.07.001","article-title":"Extracellular volume quantification by dynamic equilibrium cardiac computed tomography in cardiac amyloidosis","volume":"9","author":"Treibel","year":"2015","journal-title":"J\u00a0Cardiovasc Comput Tomogr"},{"key":"10.1016\/j.jaccao.2022.08.009_bib60","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1007\/s10554-014-0436-6","article-title":"Myocardial signal intensity decay after gadolinium injection: a fast and effective method for the diagnosis of cardiac amyloidosis","volume":"30","author":"Aquaro","year":"2014","journal-title":"Int J Cardiovasc Imaging"},{"key":"10.1016\/j.jaccao.2022.08.009_bib61","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1161\/CIRCULATIONAHA.115.016567","article-title":"Prognostic value of late gadolinium enhancement cardiovascular magnetic resonance in cardiac amyloidosis","volume":"132","author":"Fontana","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.jaccao.2022.08.009_bib62","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1093\/eurheartj\/ehu444","article-title":"T1 mapping and survival in systemic light-chain amyloidosis","volume":"36","author":"Banypersad","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jaccao.2022.08.009_bib63","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jcmg.2013.10.008","article-title":"Native T1 mapping in transthyretin amyloidosis","volume":"7","author":"Fontana","year":"2014","journal-title":"J\u00a0Am Coll Cardiol Img"},{"key":"10.1016\/j.jaccao.2022.08.009_bib64","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.jcmg.2012.11.013","article-title":"Noncontrast T1 mapping for the diagnosis of cardiac amyloidosis","volume":"6","author":"Karamitsos","year":"2013","journal-title":"J\u00a0Am Coll Cardiol Img"},{"key":"10.1016\/j.jaccao.2022.08.009_bib65","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jcmg.2013.09.019","article-title":"CMR imaging with rapid visual T1 assessment predicts mortality in patients suspected of cardiac amyloidosis","volume":"7","author":"White","year":"2014","journal-title":"J\u00a0Am Coll Cardiol Img"},{"key":"10.1016\/j.jaccao.2022.08.009_bib66","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.119.009901","article-title":"Diffusion tensor cardiovascular magnetic resonance in cardiac amyloidosis","volume":"13","author":"Khalique","year":"2020","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.jaccao.2022.08.009_bib67","article-title":"Noninvasive mapping of the electrophysiological substrate in cardiac amyloidosis and its relationship to structural abnormalities","volume":"8","author":"Orini","year":"2019","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jaccao.2022.08.009_bib68","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0735-1097(00)00531-3","article-title":"Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure","volume":"35","author":"Green","year":"2000","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jaccao.2022.08.009_bib69","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/joim.13169","article-title":"Systemic amyloidosis from A (AA) to T (ATTR): a review","volume":"289","author":"Muchtar","year":"2021","journal-title":"J\u00a0Intern Med"},{"key":"10.1016\/j.jaccao.2022.08.009_bib70","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1182\/blood-2011-06-358507","article-title":"Immunohistochemistry in the classification of systemic forms of amyloidosis: a systematic investigation of 117 patients","volume":"119","author":"Sch\u00f6nland","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jaccao.2022.08.009_bib71","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1080\/13506129.2019.1688289","article-title":"Immunoelectron microscopy and mass spectrometry for classification of amyloid deposits","volume":"27","author":"Abildgaard","year":"2020","journal-title":"Amyloid"},{"key":"10.1016\/j.jaccao.2022.08.009_bib72","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1007\/s00259-018-4013-4","article-title":"Diagnostic accuracy of bone scintigraphy in the assessment of cardiac transthyretin-related amyloidosis: a bivariate meta-analysis","volume":"45","author":"Treglia","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.jaccao.2022.08.009_bib73","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1253\/circrep.CR-19-0015","article-title":"Utility of 99 mTc-pyrophosphate scintigraphy in diagnosing transthyretin cardiac amyloidosis in real-world practice","volume":"1","author":"Tsutsui","year":"2019","journal-title":"Circ Rep"},{"key":"10.1016\/j.jaccao.2022.08.009_bib74","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1161\/CIRCIMAGING.112.000132","article-title":"99mTc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses","volume":"6","author":"Bokhari","year":"2013","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.jaccao.2022.08.009_bib75","first-page":"1041","article-title":"Diagnostic performance of imaging investigations in detecting and differentiating cardiac amyloidosis: a systematic review and meta-analysis","volume":"6","author":"Brownrigg","year":"2019","journal-title":"ESC Heart\u00a0Failure"},{"key":"10.1016\/j.jaccao.2022.08.009_bib76","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1161\/CIRCULATIONAHA.107.186093","article-title":"The role of endomyocardial biopsy in the management of cardiovascular disease","volume":"116","author":"Cooper","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.jaccao.2022.08.009_bib77","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.mayocp.2015.06.009","article-title":"Treatment of immunoglobulin light chain amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement","volume":"90","author":"Dispenzieri","year":"2015","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jaccao.2022.08.009_bib78","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/13506129.2020.1868810","article-title":"Clarification on the definition of complete haematologic response in light-chain (AL) amyloidosis","volume":"28","author":"Palladini","year":"2021","journal-title":"Amyloid"},{"key":"10.1016\/j.jaccao.2022.08.009_bib79","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/ajh.23898","article-title":"Kinetics of organ response and survival following normalization of the serum free light chain ratio in AL amyloidosis","volume":"90","author":"Kaufman","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jaccao.2022.08.009_bib80","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1182\/blood-2014-04-570010","article-title":"A\u00a0staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis","volume":"124","author":"Palladini","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jaccao.2022.08.009_bib81","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/ajh.20381","article-title":"Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004","volume":"79","author":"Gertz","year":"2005","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jaccao.2022.08.009_bib82","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1002\/ajh.25149","article-title":"Immunoglobulin light chain amyloidosis: 2018 update on diagnosis, prognosis, and treatment","volume":"93","author":"Gertz","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jaccao.2022.08.009_bib83","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s41408-018-0080-9","article-title":"Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2018","volume":"8","author":"Gertz","year":"2018","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.jaccao.2022.08.009_bib84","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/238961","article-title":"Autologous stem cell transplant for AL amyloidosis","volume":"2012","author":"Roy","year":"2012","journal-title":"Bone Marrow Res"},{"key":"10.1016\/j.jaccao.2022.08.009_bib85","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1002\/ajh.24453","article-title":"Induction therapy pre-autologous stem cell transplantation in immunoglobulin light chain amyloidosis: a retrospective evaluation","volume":"91","author":"Hwa","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jaccao.2022.08.009_bib86","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1038\/bmt.2013.53","article-title":"Patients with immunoglobulin light chain amyloidosis undergoing autologous stem cell transplantation have superior outcomes compared with patients with multiple myeloma: a retrospective review from a tertiary referral center","volume":"48","author":"Dispenzieri","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jaccao.2022.08.009_bib88","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1056\/NEJMoa2028631","article-title":"Daratumumab-based treatment for immunoglobulin light-chain amyloidosis","volume":"385","author":"Kastritis","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaccao.2022.08.009_bib89","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1182\/blood.2019004460","article-title":"Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of andromeda","volume":"136","author":"Palladini","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jaccao.2022.08.009_bib90","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1080\/10428194.2018.1485914","article-title":"Daratumumab for the treatment of AL amyloidosis","volume":"60","author":"Sidiqi","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jaccao.2022.08.009_bib92","first-page":"430","article-title":"Treatment tolerability in patients with immunoglobulin light-chain amyloidosis","volume":"11","author":"Rizio","year":"2018","journal-title":"Am Health Drug Benefits"},{"key":"10.1016\/j.jaccao.2022.08.009_bib93","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1080\/14728214.2020.1803829","article-title":"Emerging drugs for the treatment of light chain amyloidosis","volume":"25","author":"Chakraborty","year":"2020","journal-title":"Expert Opin Emerg Drugs"},{"key":"10.1016\/j.jaccao.2022.08.009_bib94","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/bjh.16401","article-title":"Use of ixazomib, lenalidomide and dexamethasone in patients with relapsed amyloid light-chain amyloidosis","volume":"189","author":"Cohen","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jaccao.2022.08.009_bib95","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1200\/JCO.19.01721","article-title":"Bendamustine with dexamethasone in relapsed\/refractory systemic light-chain amyloidosis: results of a phase II study","volume":"38","author":"Lentzsch","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jaccao.2022.08.009_bib96","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/s41375-021-01317-y","article-title":"A\u00a0randomized phase 3 study of ixazomib-dexamethasone versus physician\u2019s choice in relapsed or refractory AL amyloidosis","volume":"36","author":"Dispenzieri","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.jaccao.2022.08.009_bib97","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s13256-020-02405-w","article-title":"Droxidopa as an effective treatment for refractory neurogenic orthostatic hypotension and reflex bradycardia in amyloid light-chain amyloidosis: a case report","volume":"14","author":"Ho","year":"2020","journal-title":"J\u00a0Med Case Rep"},{"key":"10.1016\/j.jaccao.2022.08.009_bib98","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1182\/blood-2020-139102","article-title":"Updates on emerging therapies in cardiac light chain (AL) amyloidosis","volume":"136","author":"Ehsan","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jaccao.2022.08.009_bib99","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.624573","article-title":"Beyond andromeda: improving therapy for light chain amyloidosis","volume":"10","author":"Kaufman","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.jaccao.2022.08.009_bib100","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1182\/blood-2020-137235","article-title":"Safety, tolerability and efficacy of CAEL-101 in AL amyloidosis patients treated on a phase 2, open-label, dose selection study to evaluate the safety and tolerability of CAEL-101 in patients with AL amyloidosis","volume":"136","author":"Khouri","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jaccao.2022.08.009_bib101","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1182\/blood-2020-139323","article-title":"CAEL-101 is well-tolerated in AL amyloidosis patients receiving concomitant cyclophosphamide-bortezomib-dexamethasone (CyBorD): a phase 2 dose-finding study (NCT04304144)","volume":"136","author":"Valent","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jaccao.2022.08.009_bib102","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1182\/hematology.2020006913","article-title":"Management of AL amyloidosis in 2020","volume":"2020","author":"Palladini","year":"2020","journal-title":"Hematology"},{"key":"10.1016\/j.jaccao.2022.08.009_bib103","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan3128","article-title":"Repeat doses of antibody to serum amyloid P component clear amyloid deposits in patients with systemic amyloidosis","volume":"10","author":"Richards","year":"2018","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jaccao.2022.08.009_bib104","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/s41408-021-00483-7","article-title":"Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2021","volume":"11","author":"Hasib Sidiqi","year":"2021","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.jaccao.2022.08.009_bib105","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1159\/000506919","article-title":"Cardiac care of patients with cardiac amyloidosis","volume":"143","author":"Itzhaki Ben Zadok","year":"2020","journal-title":"Acta Haematol"},{"key":"10.1016\/j.jaccao.2022.08.009_bib106","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/j.jcmg.2020.02.025","article-title":"Improved quantification of cardiac amyloid burden in systemic light chain amyloidosis: redefining early disease?","volume":"13","author":"Cuddy","year":"2020","journal-title":"J\u00a0Am Coll Cardiol Img"},{"key":"10.1016\/j.jaccao.2022.08.009_bib107","first-page":"853","article-title":"Immunotherapy in systemic primary (AL) amyloidosis using amyloid-reactive monoclonal antibodies","volume":"18","author":"Solomon","year":"2003","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1016\/j.jaccao.2022.08.009_bib108","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/bjh.16436","article-title":"Monoclonal antibodies in the treatment of AL amyloidosis: co-targetting the plasma cell clone and amyloid deposits","volume":"189","author":"Popkova","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jaccao.2022.08.009_bib109","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0052686","article-title":"AL amyloid imaging and therapy with a monoclonal antibody to a cryptic epitope on amyloid fibrils","volume":"7","author":"Wall","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.jaccao.2022.08.009_bib110","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1200\/JCO.2015.63.6530","article-title":"First-in-human phase I\/II study of NEOD001 in patients with light chain amyloidosis and persistent organ dysfunction","volume":"34","author":"Gertz","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jaccao.2022.08.009_bib111","doi-asserted-by":"crossref","first-page":"E506","DOI":"10.1002\/ajh.24563","article-title":"Organ response in patients with AL amyloidosis treated with NEOD001, an amyloid-directed monoclonal antibody","volume":"91","author":"Gertz","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jaccao.2022.08.009_bib112","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1021\/bi0616605","article-title":"Localization of a conformational epitope common to non-native and fibrillar immunoglobulin light chains","volume":"46","author":"O\u2019Nuallain","year":"2007","journal-title":"Biochemistry"},{"key":"10.1016\/j.jaccao.2022.08.009_bib113","first-page":"3831s","article-title":"Therapeutic potential of chimeric amyloid-reactive monoclonal antibody 11-1f4","volume":"9","author":"Solomon","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jaccao.2022.08.009_bib114","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1182\/blood-2010-03-273797","article-title":"Radioimmunodetection of amyloid deposits in patients with AL amyloidosis","volume":"116","author":"Wall","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jaccao.2022.08.009_bib115","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/S0002-9440(10)64639-1","article-title":"Antibody-mediated resolution of light chain-associated amyloid deposits","volume":"157","author":"Hrncic","year":"2000","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jaccao.2022.08.009_bib116","first-page":"2016","article-title":"Radioimaging of light chain amyloid with a fibril-reactive monoclonal antibody","volume":"47","author":"Wall","year":"2006","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.jaccao.2022.08.009_bib117","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1080\/13506129.2019.1584892","article-title":"One year follow up analysis of the phase 1a\/b study of chimeric fibril-reactive monoclonal antibody 11-1f4 in patients with AL amyloidosis","volume":"26","author":"Edwards","year":"2019","journal-title":"Amyloid"},{"key":"10.1016\/j.jaccao.2022.08.009_bib118","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1080\/13506129.2017.1292900","article-title":"Interim analysis of the phase 1a\/b study of chimeric fibril-reactive monoclonal antibody 11-1f4 in patients with AL amyloidosis","volume":"24","author":"Edwards","year":"2017","journal-title":"Amyloid"},{"key":"10.1016\/j.jaccao.2022.08.009_bib119","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0257189","article-title":"Dexamethasone is associated with early deaths in light chain amyloidosis patients with severe cardiac involvement","volume":"16","author":"B\u00e9zard","year":"2021","journal-title":"PLoS ONE"},{"key":"10.1016\/j.jaccao.2022.08.009_bib120","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ejca.2017.02.004","article-title":"Sequential cyclophosphamide-bortezomib-dexamethasone unmasks the harmful cardiac effect of dexamethasone in primary light-chain cardiac amyloidosis","volume":"76","author":"Le Bras","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jaccao.2022.08.009_bib121","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/j.clinthera.2018.12.003","article-title":"Cyclophosphamide\u00a0+ thalidomide\u00a0+ dexamethasone versus melphalan\u00a0+ dexamethasone for the treatment of amyloid light-chain amyloidosis with kidney involvement: a retrospective study in Chinese patients","volume":"41","author":"Liu","year":"2019","journal-title":"Clin Ther"},{"key":"10.1016\/j.jaccao.2022.08.009_bib122","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1111\/ejh.13582","article-title":"Autologous stem cell transplantation vs bortezomib based chemotherapy for the first-line treatment of systemic light chain amyloidosis in the UK","volume":"106","author":"Sharpley","year":"2021","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jaccao.2022.08.009_bib123","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/s41408-021-00510-7","article-title":"Impact of early response on outcomes in AL amyloidosis following treatment with frontline bortezomib","volume":"11","author":"Ravichandran","year":"2021","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.jaccao.2022.08.009_bib124","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1038\/s41375-020-0802-4","article-title":"Systemic amyloidosis: moving into the spotlight","volume":"34","author":"Cohen","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.jaccao.2022.08.009_bib125","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1182\/bloodadvances.2019000776","article-title":"Organ responses with daratumumab therapy in previously treated AL amyloidosis","volume":"4","author":"Chung","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jaccao.2022.08.009_bib126","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1182\/blood.2019004436","article-title":"Safety, tolerability, and response rates of daratumumab in relapsed AL amyloidosis: results of a phase 2 study","volume":"135","author":"Sanchorawala","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jaccao.2022.08.009_bib127","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1182\/asheducation-2010.1.287","article-title":"Systemic light-chain amyloidosis: advances in diagnosis, prognosis, and therapy","volume":"2010","author":"Cohen","year":"2010","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.jaccao.2022.08.009_bib128","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/bjh.13805","article-title":"Recent advances in the management of AL amyloidosis","volume":"172","author":"Kastritis","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jaccao.2022.08.009_bib129","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/bjh.17685","article-title":"Lenalidomide and dexamethasone in relapsed\/refractory immunoglobulin light chain (AL) amyloidosis: results from a large cohort of patients with long follow-up","volume":"195","author":"Basset","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jaccao.2022.08.009_bib130","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1159\/000507072","article-title":"Conventional therapy for amyloid light-chain amyloidosis","volume":"143","author":"Milani","year":"2020","journal-title":"Acta Haematologica"},{"key":"10.1016\/j.jaccao.2022.08.009_bib131","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41408-020-00397-w","article-title":"Venetoclax induces deep hematologic remissions in t(11;14) relapsed\/refractory AL amyloidosis","volume":"11","author":"Premkumar","year":"2021","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.jaccao.2022.08.009_bib132","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1159\/000506760","article-title":"Supportive care in AL amyloidosis","volume":"143","author":"Cibeira","year":"2020","journal-title":"Acta Haematologica"},{"key":"10.1016\/j.jaccao.2022.08.009_bib133","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.hoc.2020.08.007","article-title":"Supportive care for patients with systemic light chain amyloidosis","volume":"34","author":"Wong","year":"2020","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.jaccao.2022.08.009_bib135","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1038\/s41375-018-0060-x","article-title":"Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria","volume":"32","author":"Muchtar","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.jaccao.2022.08.009_bib136","doi-asserted-by":"crossref","DOI":"10.1177\/1753944719870084","article-title":"6-Minute walking test: a useful tool in the management of heart failure patients","volume":"13","author":"Giannitsi","year":"2019","journal-title":"Ther Adv Cardiovasc Dis"},{"key":"10.1016\/j.jaccao.2022.08.009_bib137","first-page":"599","article-title":"Longitudinal associations between health-related quality of life and healthcare utilization in AL amyloidosis","volume":"102","author":"Bayliss","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.jaccao.2022.08.009_bib138","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1182\/blood-2020-139438","article-title":"Health-related quality of life in patients with AL amyloidosis treated with daratumumab, bortezomib, cyclophosphamide, and dexamethasone: results from the phase 3 Andromeda study","volume":"136","author":"Sanchorawala","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jaccao.2022.08.009_bib139","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1111\/bjh.15693","article-title":"Cardiac biomarkers and health-related quality of life in patients with light chain (AL) amyloidosis","volume":"185","author":"McCausland","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jaccao.2022.08.009_bib140","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.jhep.2009.07.010","article-title":"A\u00a0review of quality of life instruments used in liver transplantation","volume":"51","author":"Jay","year":"2009","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jaccao.2022.08.009_bib141","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1159\/000484115","article-title":"Comparison of quality of life in patients undergoing hemodialysis and peritoneal dialysis: a systematic review and meta-analysis","volume":"42","author":"Zazzeroni","year":"2017","journal-title":"Kidney Blood Press Res"},{"key":"10.1016\/j.jaccao.2022.08.009_bib142","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1093\/ehjci\/jeaa146","article-title":"Time trajectory of cardiac function and its relation with survival in patients with light-chain cardiac amyloidosis","volume":"22","author":"Hwang","year":"2021","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.jaccao.2022.08.009_bib143","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s12872-021-01856-3","article-title":"Predictors of cardiac involvement and survival in patients with primary systemic light-chain amyloidosis: roles of the clinical, chemical, and 3-D speckle tracking echocardiography parameters","volume":"21","author":"Lei","year":"2021","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.jaccao.2022.08.009_bib144","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/S0735-1097(20)31633-8","article-title":"Incremental value of GLS for classification of prognosis in patients with advanced light chain (AL) amyloidosis","volume":"75","author":"Nahhas","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jaccao.2022.08.009_bib145","first-page":"223","article-title":"Incremental value of global longitudinal strain for predicting survival in patients with advanced AL amyloidosis","volume":"2","author":"Chuy","year":"2020","journal-title":"J\u00a0Am Coll Cardiol CardioOnc"},{"key":"10.1016\/j.jaccao.2022.08.009_bib146","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.2967\/jnumed.118.221770","article-title":"Early detection of multiorgan light-chain amyloidosis by whole-body 18F-florbetapir PET\/CT","volume":"60","author":"Ehman","year":"2019","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.jaccao.2022.08.009_bib147","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1007\/s00259-019-04627-7","article-title":"Quantitative [18F]florbetapir PET\/CT may identify lung involvement in patients with systemic AL amyloidosis","volume":"47","author":"Khor","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.jaccao.2022.08.009_bib148","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1007\/s10554-021-02190-7","article-title":"Deep-learning-based cardiac amyloidosis classification from early acquired PET images","volume":"37","author":"Santarelli","year":"2021","journal-title":"Int J Cardiovasc Imaging"},{"key":"10.1016\/j.jaccao.2022.08.009_bib149","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1007\/s12350-021-02608-8","article-title":"Cardiac amyloidosis characterization by kinetic model fitting on [18F]florbetaben PET images","volume":"29","author":"Santarelli","year":"2021","journal-title":"J\u00a0Nucl Cardiol"},{"key":"10.1016\/j.jaccao.2022.08.009_bib150","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.2174\/1381612826666200813133557","article-title":"Imaging techniques as an aid in the early detection of cardiac amyloidosis","volume":"27","author":"Santarelli","year":"2021","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.jaccao.2022.08.009_bib151","doi-asserted-by":"crossref","first-page":"e503","DOI":"10.1097\/RLU.0000000000002699","article-title":"Clinical utility of 18F-florbetaben PET for detecting amyloidosis associated with multiple myeloma: a prospective case-control study","volume":"44","author":"Seo","year":"2019","journal-title":"Clin Nucl Med"}],"container-title":["JACC: CardioOncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266608732200391X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266608732200391X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T18:55:36Z","timestamp":1762973736000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S266608732200391X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":148,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S266608732200391X"],"URL":"https:\/\/doi.org\/10.1016\/j.jaccao.2022.08.009","relation":{},"ISSN":["2666-0873"],"issn-type":[{"value":"2666-0873","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"AL Amyloidosis for Cardiologists","name":"articletitle","label":"Article Title"},{"value":"JACC: CardioOncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaccao.2022.08.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}